- Home
- NAMS
NAMS
NewAmsterdam Pharma Company N.V.
as 03-28-2025 4:00pm EST
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $43.17 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.19 - $27.29 | Next Earning Date: | 05-05-2025 |
| Revenue: | $45,563,000 | Revenue Growth: | 223.37% |
| Revenue Growth (this year): | -62.95% | Revenue Growth (next year): | 2.54% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year
Simply Wall St.
a month ago
NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
a month ago
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
Simply Wall St.
a month ago
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease
GlobeNewswire
2 months ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
GlobeNewswire
3 months ago
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.